We are a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Glaucoma is one of the largest segments in the global ophthalmic market. In 2013, branded and generic glaucoma product sales exceeded $4.5 billion in the United States, Europe and Japan in aggregate, according to IMS. Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, resulting in irreversible vision loss and potentially blindness.

from http://www.aeriepharma.com/aerieabout.html

Publications 23 show all

  • 11
    beta-Alanine/analogs & derivatives
  • 8
    Glaucoma, Open-Angle/drug therapy
  • 8
    Intraocular Pressure/drug effects
  • 7
    rho-Associated Kinases/antagonists & inhibitors
  • 5
    Antihypertensive Agents/therapeutic use
  • 4
    Benzoates/pharmacology
  • 4
    Benzoates/therapeutic use
  • 4
    Ocular Hypertension/drug therapy
  • 3
    Benzoates/administration & dosage
  • 3
    Intraocular Pressure/physiology

Patents 176show all

  • 28
    C07D - Heterocyclic compounds
  • 12
    C07C - Acyclic or carbocyclic compounds
  • 7
    A61K - Preparations for medical, dental, or toilet purposes
  • 3
    A61B - Diagnosis
  • 3
    A61F - Filters implantable into blood vessels
  • 3
    A61M - Devices for introducing media into, or onto, the body
  • 2
    C07B - General methods of organic chemistry

Clinical Trials 31show all

17Phase 27Phase 34Phase 12Other

SEC Filings show all


197
8-K

20
10-Q

7
10-K

5
D

1
S-1

Contact Information

Morrisville, NC
United States